Liminatus Pharma, Inc.
LIMN
$0.98
$0.077.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | 44.55% | -- | -- | -- | |
| Total Depreciation and Amortization | -- | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -- | -- | -- | -- | |
| Change in Net Operating Assets | -396.39% | -- | -- | -- | |
| Cash from Operations | -496.39% | -- | -- | -- | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 52.15% | -- | -- | -- | |
| Cash from Investing | 61.43% | -- | -- | -- | |
| Total Debt Issued | 9.02% | -- | -- | -- | |
| Total Debt Repaid | -550.00% | -- | -- | -- | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 110.00% | -- | -- | -- | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 276.63% | -- | -- | -- | |